Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$323,986 | -$356,422 | -$281,310 | -$282,089 |
| Dep. & Amort. | $13,693 | $39,146 | $19,853 | $10,250 |
| Deferred Tax | $0 | $0 | $89 | -$2,720 |
| Stock-Based Comp. | $47,813 | $52,340 | $43,434 | $36,453 |
| Change in WC | -$43,882 | $665 | -$4,774 | $39,972 |
| Other Non-Cash | $89,787 | $70,723 | $1,170 | $19,632 |
| Operating Cash Flow | -$216,575 | -$193,548 | -$221,538 | -$178,502 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$6,886 | -$23,010 | -$18,075 | -$4,216 |
| Net Acquisitions | $0 | $19,800 | $7,700 | -$818 |
| Inv. Purchases | -$263,923 | -$347,966 | -$183,590 | -$259,304 |
| Inv. Sales/Matur. | $385,432 | $232,178 | $172,000 | $276,469 |
| Other Inv. Act. | -$4,883 | -$19,800 | -$7,700 | $17,047 |
| Investing Cash Flow | $109,740 | -$138,798 | -$29,665 | $12,131 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $30,160 | $87,053 | $0 | $287,500 |
| Stock Issued | $100,183 | $248,014 | $21,706 | $83,948 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $6,224 | -$3,373 | $8,163 | -$39,964 |
| Financing Cash Flow | $136,567 | $331,694 | $29,869 | $331,484 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $29,732 | -$652 | -$221,334 | $165,113 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $115,017 | $115,669 | $337,003 | $171,890 |
| End Cash | $144,749 | $115,017 | $115,669 | $337,003 |
| Free Cash Flow | -$223,461 | -$216,558 | -$239,613 | -$182,718 |